The acquisition marks Hikma’s expansion into Canada and includes a portfolio of 25 sterile injectable products, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Riad Mishlawi, President of Hikma Injectables, commented, “The completion of this acquisition expands Hikma’s presence in the highly attractive Canadian injectables market, bringing a strong portfolio of sterile injectable products, as well as strengthening our pipeline.  We are excited to bring these important products to our Canadian customers and their patients.”